Dabigatran — Blood Clot Prevention Guide | KiwiMeds
✅ Reviewed by a Registered Pharmacist NZ | Last updated: May 2026 | This information is for educational purposes only and does not replace advice from your doctor or pharmacist.
What is dabigatran?
Dabigatran (brand name Pradaxa) is a direct oral anticoagulant (DOAC) used to prevent blood clots and strokes. It is used mainly for atrial fibrillation and to treat or prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). In NZ it is funded by Pharmac with Special Authority.
What is it used for? (NZ context)
Dabigatran is used to prevent strokes in people with non-valvular atrial fibrillation, and to treat and prevent DVT and PE. It is one of several DOACs available in NZ (alongside rivaroxaban and apixaban) as alternatives to warfarin that do not require regular INR blood test monitoring.
How does it work?
Dabigatran directly inhibits thrombin — the final enzyme in the blood clotting cascade. By blocking thrombin, it prevents fibrin clots from forming. Unlike warfarin, it works predictably without needing routine blood level monitoring and has fewer food interactions.
How to take it
Dabigatran is taken twice daily (150mg or 110mg depending on age and kidney function). It must be swallowed whole with water — do not break open capsules. Can be taken with or without food. Dabigatran has a reversal agent (idarucizumab/Praxbind) available in NZ hospitals for emergencies.
Common side effects
- Bleeding — the main risk
- Stomach upset, nausea, or heartburn (more common than other DOACs)
- Dyspepsia (indigestion)
Serious side effects to watch for
The main risk is serious bleeding — seek urgent medical attention for unusual bleeding, blood in urine or stools, severe bruising, or signs of internal bleeding. Tell all healthcare providers and surgeons you are on dabigatran. Kidney function must be monitored as dabigatran is cleared by the kidneys.
Important drug interactions
P-glycoprotein inhibitors (e.g., dronedarone, ketoconazole, clarithromycin) increase dabigatran levels — significant risk of bleeding. P-glycoprotein inducers (e.g., rifampicin) reduce dabigatran effectiveness. Aspirin and NSAIDs — increased bleeding risk. Do not combine with other anticoagulants without medical advice.
NZ-specific information
Pharmac funding: Dabigatran 110mg and 150mg capsules are funded by Pharmac under Special Authority for stroke prevention in atrial fibrillation and treatment of VTE (venous thromboembolism). Brand name: Pradaxa.
Frequently asked questions
Do I need regular blood tests on dabigatran?
Not routinely for efficacy (no INR monitoring needed). However, kidney function tests are required because dabigatran is cleared by the kidneys — impaired kidneys lead to higher drug levels and bleeding risk. Your doctor will check these periodically.
What do I do if I miss a dose of dabigatran?
Take the missed dose as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and continue with the usual schedule. Never take two doses at the same time.
Is dabigatran safer than warfarin?
DOACs like dabigatran have some advantages — no routine INR monitoring, fewer food interactions, and often a better safety profile for certain bleeding types (especially brain bleeding). However, dabigatran can cause more gastrointestinal upset than warfarin or other DOACs. Choice depends on individual factors.
💬 Talk to your pharmacist or doctor for personalised advice about dabigatran.
Reviewed by a Registered Pharmacist NZ | BPharm, Pharmacy Council of New Zealand
References & Further Information
The following New Zealand and international resources were used to inform this page: